
NucTheraIn applies AI to improve diagnosis and personalize care in nuclear medicine. It develops AI-driven diagnostic platforms that fuse imaging with radiomics and multi-omic data from PET, SPECT-CT, and MRI. The company works across radiochemistry, radiopharmaceutical access, and translational research to support precision oncology and theranostics. Partnering with academic and industrial entities, it advances clinical trial management and global access to novel isotopes and technologies.

NucTheraIn applies AI to improve diagnosis and personalize care in nuclear medicine. It develops AI-driven diagnostic platforms that fuse imaging with radiomics and multi-omic data from PET, SPECT-CT, and MRI. The company works across radiochemistry, radiopharmaceutical access, and translational research to support precision oncology and theranostics. Partnering with academic and industrial entities, it advances clinical trial management and global access to novel isotopes and technologies.